Previous 10 | Next 10 |
10x Genomics, Inc. (TXG) Q3 2020 Results Conference Call November 9, 2020 4:50 PM ET Company Participants Eric Jaschke - Director of Investor Relations and Strategic Finance Serge Saxonov - Co-Founder & Chief Executive Officer Justin McAnear - Chief Financial Officer Bradford Crutchfield ...
10x Genomics (TXG): Q3 GAAP EPS of -$0.65 misses by $0.34.Revenue of $71.8M (+17.3% Y/Y) beats by $10.61M.Shares -3%.Press Release For further details see: 10x Genomics EPS misses by $0.34, beats on revenue
PLEASANTON, Calif., Nov. 10, 2020 (GLOBE NEWSWIRE) -- 10x Genomics, Inc. (Nasdaq: TXG) today reported financial results for the third quarter ended September 30, 2020. Recent Highlights Revenue was $71.8 million for the third quarter, representing a 17% increase over the cor...
[[ADPT]], [[ALC]], [[ASH]], [[BRKS]], [[COHR]], [[CVET]], [[DDOG]], [[DOX]], [[FICO]], [[FOXF]], [[GO]], [[HCAT]], [[KRNT]], [[LYFT]], [[MODN]], [[ONEM]], [[PLMR]], [[PRPL]], [[PRSP]], [[RKT]], [[RXT]], [[SANM]], [[SILK]], [[TME]], [[TXG]]For Seeking Alpha's full earnings season calendar, cli...
10x Genomics (NASDAQ:TXG) is scheduled to announce Q3 earnings results on Tuesday, November 10th, after market close.The consensus EPS Estimate is -$0.31 (+6.1% Y/Y) and the consensus Revenue Estimate is $61.19M (-0.0% Y/Y).Over the last 3 months, EPS estimates have seen 3 upward revisio...
PLEASANTON, Calif., Nov. 04, 2020 (GLOBE NEWSWIRE) -- 10x Genomics (Nasdaq: TXG) today announced the company will be participating in the upcoming Stifel Virtual Healthcare Conference. 10x Genomics’ management is scheduled to present on Monday, November 16 at 11:40 a.m. Pacific...
Illumina's acquisition of Grail was received poorly - we disagree wholeheartedly with the market and see significant upside from the acquisition, which increases its addressable market by 10x. The company is dominant, with a ~70% market share, and is the global market leader in next-g...
PLEASANTON, Calif., Oct. 13, 2020 (GLOBE NEWSWIRE) -- 10x Genomics (Nasdaq: TXG) today announced it will report financial results for the third quarter 2020 after market close on Tuesday, November 10, 2020. The company’s management will webcast a corresponding conference call beginni...
10x Genomics acquired ReadCoor, a Boston developer of In Situ technologies, for $350 million. Corvus Pharma formed a China subsidiary, Angel Pharma, to develop its three clinical-stage assets and one preclinical platform in China. Zai Lab of Shanghai has dosed the first patient in...
Continuing on its mission of mastering biology to advance human health, 10x Genomics (TXG) to acquire ReadCoor for cash and stock consideration of $350M.The announcement follows acquisition of Stockholm-based CartaNA AB, developers of In Situ RNA analysis technology, in late August.As a resul...
News, Short Squeeze, Breakout and More Instantly...
2024-07-23 06:00:09 ET Kyle Mikson from Canaccord Genuity issued a price target of $32.00 for TXG on 2024-07-23 05:09:00. The adjusted price target was set to $32.00. At the time of the announcement, TXG was trading at $18.11. The overall price target consensus is at $24...
10x Genomics to Report Second Quarter 2024 Financial Results on August 8, 2024 PR Newswire PLEASANTON, Calif. , July 12, 2024 /PRNewswire/ -- 10x Genomics, Inc. (Nasdaq: TXG), a leader in single cell and spatial biology, today announced that it will report fi...
A look at the top 10 most actives in the United States Kazia Therapeutics Limited (KZIA) rose 248.0% to $0.6682 on volume of 430,252,408 shares Maxeon Solar Technologies Ltd. (MAXN) fell 15.0% to $0.2108 on volume of 237,403,092 shares NVIDIA Corporation (NVDA) rose 2.7% to $134.91 on vol...